Concord Biotech (BOM:543960) Debt-to-Revenue : 0.01 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Concord Biotech Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Concord Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹79 Mil. Concord Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹19 Mil. Concord Biotech's annualized Revenue for the quarter that ended in Mar. 2024 was ₹11,195 Mil. Concord Biotech's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.01.

Concord Biotech Debt-to-Revenue Historical Data

The historical data trend for Concord Biotech's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Biotech Debt-to-Revenue Chart

Concord Biotech Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Revenue

0.10

0.15

0.09

0.04

0.01

Concord Biotech Semi-Annual Data
	Mar20	Mar21	Mar22	Sep22	Mar23	Sep23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial			N/A	-	0.03	0.03	0.01

Competitive Comparison of Concord Biotech's Debt-to-Revenue

For the Biotechnology subindustry, Concord Biotech's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Concord Biotech's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Concord Biotech's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Concord Biotech's Debt-to-Revenue falls into.

Concord Biotech Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Concord Biotech's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(78.506	+	18.87)	/	10169.392
	=	0.01

Concord Biotech's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(78.506	+	18.87)	/	11195.318
	=	0.01

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Mar. 2024) Revenue data.

Concord Biotech Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Concord Biotech's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Concord Biotech (BOM:543960) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concord Biotech Ltd (BOM:543960) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

CONCORDBIO:India

Address

Iscon Cross Road, S.G. Highway, 16th floor, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015

Website

https://www.concordbiotech.com

Concord Biotech Ltd is a Research & development-driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations.

Concord Biotech (BOM:543960) Headlines

No Headlines